2019 Symposium

2018 Symposium

2017 Symposium

2016 Symposium

2015 Symposium

2014 Symposium

2013 Symposium

Previous Symposia

2015 Featured Talks » Reversing Drug Resistance in Cancer Stemness



Reversing Drug Resistance in Cancer Stemness

David Cheresh, PhD
UC San Diego Moores Cancer Center


Part One


Part Two




David Cheresh, PhD
Distinguished Professor & Vice Chair of Pathology
Associate Director for Innovation and Industry Alliances
UC San Diego Moores Cancer Center


David Cheresh studies the mechanism of action of signaling networks that regulate tumor growth stemness, drug resistance and metastasis. He discovered that ανβ3 integrin is a functional marker of angiogenic blood vessels and drives cancer stemness. His work is basic and translational focusing on new strategies for biologically-based drug development. In particular, he studies how integrings and growth factor receptors promote cell survival, angiogenesis and tumor invasion. His work has lead to the development of several drugs now in various stages of clinical development. Cheresh’s research in this area has been widely cited with seven of this peer-reviewed publications being cited >1000 times. David Cheresh was the scientific founder of TargeGen, a San Diego based Biotechnology Company which developed a number of small molecules based in part on discoveries made in the Cheresh laboratory. TargeGen’s JAK2 inhibitor has shown clinical activity in patents with myeloproliferative disease and has successfully completed phase III trials. Most recently, Cheresh and his colleagues have developed a novel scaffold based chemistry approach to stabilize kinases in their inactive state. These studies have lead to the discovery of a first in class Raf inhibitor that has distinct advantages relative to ATP mimetics of RAF. Cheresh and his colleagues at UCSD have founded a new startup company (Amitech Therapeutic Solutions, ATS) which focuses on the discovery of allosteric inhibitors of kinases such as those targeting Raf and other important molecules/pathways relevant to cancer and inflammatory disease.

Cheresh and colleagues are now focused on tumor cells that display stem like properties, and are highly aggressive often showing drug resistance. It was found that integrin avb3 serves as a marker of breast, lung and pancreatic tumors with stem-like properties that are highly resistant to receptor tyrosine kinase inhibitors such as erlotinib. This was observed in vitro and in mice bearing patient-derived tumor xenographs or in clinical specimens from lung cancer patients that had progressed on erlotinib. Mechanistically, ανβ3, in the unligated state, recruits KRAS and RalB to the tumor cell plasma membrane, leading to the activation of TBK-1/NFkB. In fact, ανβ3 and the resulting KRAS/RalB/NFkB pathway are both necessary and sufficient to promote tumor initiation, anchorage-independence, self-renewal, and erlotinib resistance. Pharmacological targeting this pathway reverses both tumor stemness and drug resistance. These findings not only identify ανβ3 as a marker/driver of tumor stemness but they reveal a therapeutic strategy to sensitize such tumors to RTK inhibition.